Biofrontera Third-Quarter Product Revenue of 9.1 Million Dollars Rises 29.8 Percent: A Gross Margin of 74.4 Percent and a Net Loss of 6.4 Million Dollars, Released November 13
Biofrontera Inc., which specializes in the development and commercialization of photodynamic therapy in dermatology, reported financial results for the quarter ended September 30, 2026 through GlobeNewswire on November 13, 2026. All figures below are from the body of the company's results release, and this report offers no investment advice.
Third-quarter net product revenue was 9.1 million dollars, an increase of 2.1 million dollars, or 29.8 percent, from 7.0 million dollars in the third quarter of 2025.
Cost of revenues was 2.3 million dollars, against 2.0 million dollars, producing gross profit of 6.7 million dollars and a gross margin of 74.4 percent, compared with gross profit of 4.9 million dollars and a gross margin of 70.7 percent in the prior-year quarter, an improvement of approximately 370 basis points. The company attributed this to the lower Ameluz cost structure established following the closing of the strategic transaction with Biofrontera AG in October 2025, partially offset by ITC matter-related inventory write-downs and higher lamp and device costs.
The net loss for the third quarter was 6.4 million dollars, or 0.42 dollars per share, compared with a net loss of 6.6 million dollars, or 0.62 dollars per share, in the prior-year quarter. Adjusted EBITDA was a loss of 5.5 million dollars, compared with a loss of 6.0 million dollars.
On September 9, 2026, Ameluz received FDA approval for the treatment of superficial basal cell carcinoma, making Ameluz plus red light the first and only photodynamic therapy approved for the treatment of cancerous skin tumors, the company said. Biofrontera hosted a conference call and webcast on November 13, 2026 at 10:00 a.m. Eastern time.
Source: Biofrontera Inc
Published by GSM · USA (original Chinese edition)
Photo: 图：Biofrontera Inc相关图(资料图)。作者与授权：Biofrontera AG，CC BY-SA 4.0，维基共享资源。 / Photo: Image related to Biofrontera Inc (file photo). Credit: Biofrontera AG, CC BY-SA 4.0, Wikimedia Commons.
British Insurer Aviva Reports Its Third Quarter 2026 Trading Update: General Insurance Premiums of 11.8 Billion Pounds, Up 19 Percent, a Combined Operating Ratio of 93.8 Percent and a Solvency II Cover Ratio of 179 Percent2026-11-14
Questerre Third-Quarter Production Averages 4,634 Barrels of Oil Equivalent per Day: Petroleum and Natural Gas Revenue of 50.8 Million Canadian Dollars and a Net Loss of 27.6 Million Canadian Dollars as the PX Energy Turnaround Finishes on Schedule, Released November 122026-11-14